August 27, 2014 11:27 AM ET


Company Overview of Calithera Biosciences, Inc.

Company Overview

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company was founded in 2010 and is headquartered in South San Francisco, California.

343 Oyster Point Boulevard

Suite 200

South San Francisco, CA 94080

United States

Founded in 2010



Key Executives for Calithera Biosciences, Inc.

Age: 60
Chief Financial Officer and Senior Vice President
Age: 56
Senior Director of Human Resources and Operations
Senior Vice President of Research
Senior Vice President of Drug Discovery
Compensation as of Fiscal Year 2014.

Calithera Biosciences, Inc. Key Developments

Calithera Biosciences Seeks Acquisitions

Calithera Biosciences, Inc. will consider acquisitions. Calithera Biosciences has filed an IPO in the amount of $80 million. The proceeds from the offering may be used to acquire complementary businesses, products or technologies, although, Calithera Biosciences has no present commitments or agreements for any specific acquisitions.

Calithera Biosciences, Inc. Presents at BIO International Convention, Jun-24-2014 04:15 PM

Calithera Biosciences, Inc. Presents at BIO International Convention, Jun-24-2014 04:15 PM. Venue: San Diego Convention Center, San Diego, California, United States.

Calithera Biosciences Appoints William D. Waddill as Senior Vice President, Chief Financial Officer, Effective from April 1, 2014

Calithera Biosciences announced the appointment of William D. Waddill as Senior Vice President, Chief Financial Officer, effective April 1, 2014. As CFO, Mr. Waddill will provide input on corporate strategy and oversee all corporate financial matters, including financial planning and reporting, as well as investor relations. He will report directly to Susan Molineaux, PhD, President and Chief Executive Officer. Mr. Waddill joins Calithera from OncoMed Pharmaceuticals where he served as Senior Vice President, CFO since 2007 responsible for all corporate financial matters, most notably the successfully completed $94 million Initial Public Offering in July 2013, private equity financing of $126 million in December 2008, and three collaborations valued at $6.1 billion.

Similar Private Companies By Industry

Company Name Region
Cornerstone BioPharma Holdings, Inc. United States
Zeneca Holdings Inc. United States
Astra Usa, Inc United States
Xel Pharmaceuticals, Inc. United States
JDP Therapeutics, Inc. United States

Recent Private Companies Transactions

Private Placement
July 1, 2014
Private Placement
October 7, 2013

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Calithera Biosciences, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at